BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2015;55:1395-405. [PMID: 26011596 DOI: 10.1002/jcph.550] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
2 Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. Int J Hepatol. 2018;2018:8432781. [PMID: 29973997 DOI: 10.1155/2018/8432781] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
3 Intagliata NM, Maitland H, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14:247-256. [PMID: 27020266 DOI: 10.1007/s11938-016-0092-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
4 Douros A, Cui Y, Platt RW, Filion KB, Sebastiani G, Renoux C. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. Br J Clin Pharmacol 2021. [PMID: 34409636 DOI: 10.1111/bcp.15046] [Reference Citation Analysis]
5 Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations. Can J Gastroenterol Hepatol. 2019;2019:4383269. [PMID: 30792971 DOI: 10.1155/2019/4383269] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Foody JM. Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. Clin Interv Aging 2017;12:175-87. [PMID: 28182166 DOI: 10.2147/CIA.S111216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
7 Shirley M, Dhillon S. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. Drugs 2015;75:2025-34. [PMID: 26546477 DOI: 10.1007/s40265-015-0495-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol 2017;10:5-15. [PMID: 27817212 DOI: 10.1080/17512433.2016.1258301] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Finks SW, Trujillo TC, Dobesh PP. Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother 2016;50:486-501. [PMID: 26917821 DOI: 10.1177/1060028016632785] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
10 Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol 2019;74:179-89. [PMID: 31296289 DOI: 10.1016/j.jacc.2019.04.061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
11 Rali P, Gangemi A, Moores A, Mohrien K, Moores L. Direct-Acting Oral Anticoagulants in Critically Ill Patients. Chest 2019;156:604-18. [PMID: 31251908 DOI: 10.1016/j.chest.2019.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Duchin K, Duggal A, Atiee GJ, Kidokoro M, Takatani T, Shipitofsky NL, He L, Zhang G, Kakkar T. An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. Clin Pharmacokinet 2018;57:221-8. [PMID: 28512699 DOI: 10.1007/s40262-017-0554-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
13 Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci. 2016;61:1721-1727. [PMID: 26725062 DOI: 10.1007/s10620-015-4012-2] [Cited by in Crossref: 135] [Cited by in F6Publishing: 110] [Article Influence: 22.5] [Reference Citation Analysis]
14 Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol 2018;71:2162-75. [PMID: 29747837 DOI: 10.1016/j.jacc.2018.03.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 19.3] [Reference Citation Analysis]
15 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res 2018;170:102-8. [PMID: 30153564 DOI: 10.1016/j.thromres.2018.08.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
16 Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet 2016;55:641-55. [PMID: 26620048 DOI: 10.1007/s40262-015-0342-7] [Cited by in Crossref: 106] [Cited by in F6Publishing: 78] [Article Influence: 21.2] [Reference Citation Analysis]
17 Verbeek TA, Stine JG, Saner FH, Bezinover D. Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management. Transplant Direct 2018;4:e403. [PMID: 30534594 DOI: 10.1097/TXD.0000000000000843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
18 Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol 2016;82:1591-600. [PMID: 27530188 DOI: 10.1111/bcp.13092] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
19 Toyoda J, Morioka D, Horii N, Nakayama G, Oyama N, Asano F, Izumisawa Y, Miura M, Sato Y, Endo I. Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report. J Med Case Rep 2021;15:52. [PMID: 33563326 DOI: 10.1186/s13256-020-02651-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Lemay A, Kaye AD, Urman RD. Novel Anticoagulant Agents in the Perioperative Setting. Anesthesiol Clin 2017;35:305-13. [PMID: 28526151 DOI: 10.1016/j.anclin.2017.01.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
21 Bertoletti L, Ollier E, Duvillard C, Delavenne X, Beyens M, De Magalhaes E, Bellet F, Basset T, Mismetti P, Laporte S. Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research 2017;118:33-42. [DOI: 10.1016/j.phrs.2016.06.023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
22 Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, Bellosta S. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018;135:60-79. [PMID: 30040996 DOI: 10.1016/j.phrs.2018.07.016] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
23 Salerno DM, Tsapepas D, Papachristos A, Chang JH, Martin S, Hardy MA, McKeen J. Direct oral anticoagulant considerations in solid organ transplantation: A review. Clin Transplant. 2017;31. [PMID: 27859621 DOI: 10.1111/ctr.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
24 Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol 2019;15:381-98. [PMID: 30951640 DOI: 10.1080/17425255.2019.1604686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
25 Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Regional Anesthesia and Pain Medicine 2018;43:263-309. [DOI: 10.1097/aap.0000000000000763] [Cited by in Crossref: 287] [Cited by in F6Publishing: 70] [Article Influence: 71.8] [Reference Citation Analysis]
26 Barrios V, Escobar C. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiology 2016;12:419-33. [DOI: 10.2217/fca-2016-0021] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Voukalis C, Lip GY, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol 2016;12:1445-61. [PMID: 27535163 DOI: 10.1080/17425255.2016.1225037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
28 Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 2019;17:319-30. [DOI: 10.1080/14779072.2019.1598263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]